Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Cha, Yoon Jin ^a   Lee, Jae Seok ^a   Kim, Hye Ryun ^b   Lim, Sun Min ^b   Cho, Byoung Chul ^b   Lee, Chang Young ^a   Shim, Hyo Sup ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN ROS1; TUMOR PROTEIN; UNCLASSIFIED DRUG; ANAPLASTIC LYMPHOMA KINASE; ONCOPROTEIN; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN;

ADULT; AGED; ALK GENE; ARTICLE; CANCER SCREENING; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; ROS1 GENE; SENSITIVITY AND SPECIFICITY; SMOKING; ADENOCARCINOMA; FLUORESCENT ANTIBODY TECHNIQUE; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PROCEDURES; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84904910906     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103333     Document Type: Article

References (26)

1. Li T, Kung H-J, Mack PC, Gandara DR (2013) Genotyping and Genomic Profiling of Non-Small-Cell Lung Cancer: Implications for Current and Future Therapies. J Clin Oncol 31: 1039-1049.
2. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, et al. (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8: 823-859.
3. Oxnard GR, Binder A, Jänne PA (2013) New Targetable Oncogenes in Non-Small-Cell Lung Cancer. J Clin Oncol 31: 1097-1104.
4. Ou S-HI, Tan J, Yen Y, Soo RA (2012) ROS1 as a 'druggable'receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. Expert Rev Anticancer Ther 12: 447-456.
5. Gainor JF, Varghese AM, Ou S-HI, Kabraji S, Awad MM, et al. (2013) ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer. Clin Cancer Res 19: 4273-4281.
6. Bergethon K, Shaw AT, Ignatius Ou S-H, Katayama R, Lovly CM, et al. (2012) ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers. J Clin Oncol 30: 863-870.
7. Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, et al. (2013) The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol 24: 2364-2370.
8. Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, et al. (2013) Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. N Engl J Med 368: 2385-2394.
9. Karachaliou N, Rosell R (2013) Optimal Detection of ALK Rearranged Lung Adenocarcinomas. J Thorac Oncol 8: 255-256.
10. Jänne PA, Meyerson M (2012) ROS1 Rearrangements in Lung Cancer: A New Genomic Subset of Lung Adenocarcinoma. J Clin Oncol 30: 878-879.
11. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, et al. (2010) A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 16: 1561-1571.
12. Ying J, Guo L, Qiu T, Shan L, Ling Y, et al. (2013) Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol 24: 2589-2593.
13. Selinger CI, Rogers TM, Russell PA, O'Toole S, Yip P, et al. (2013) Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 26: 1545-1553.
14. Zhang Y-G, Jin M-L, Li L, Zhao H-Y, Zeng X, et al. (2013) Evaluation of ALK Rearrangement in Chinese Non-Small Cell Lung Cancer Using FISH, Immunohistochemistry, and Real-Time Quantitative RT- PCR on Paraffin-Embedded Tissues. PLoS ONE 8: e64821.
15. Takamochi K, Takeuchi K, Hayashi T, Oh S, Suzuki K (2013) A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients. PLoS One 8: e69794.
16. Yoshida A, Tsuta K, Wakai S, Arai Y, Asamura H, et al. (2014) Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod Pathol 27: 711-720.
17. Sholl LM, Sun H, Butaney M, Zhang C, Lee C, et al. (2013) ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas. Am J Surg Pathol 37: 1441-1449.
18. Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, et al. (2012) Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non-Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion. Clin Cancer Res 18: 4449-4457.
19. Mescam-Mancini L, Lantuéjoul S, Moro-Sibilot D, Rouquette I, Souquet P-J, et al. (2014) On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer 83: 168-173.
20. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, et al. (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244-285.
21. Noh S, Shim H (2012) Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas. Lung Cancer 76: 51-55.
22. Han H-S, Lim S-n, An JY, Lee KM, Choe KH, et al. (2012) Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity. J Thorac Oncol 7: 355-364.
23. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
24. Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, et al. (2011) Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas. Am J Surg Pathol 35: 1226-1234.
25. Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, et al. (2013) CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 14: 590-598.
26. Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y, et al. (2013) ROS1-Rearranged Lung Cancer: A Clinicopathologic and Molecular Study of 15 Surgical Cases. Am J Surg Pathol 37: 554-562.